T. Rowe Price Associates’s UroGen Pharma URGN Stock Holding History

T. Rowe Price Associates’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Buy	35,003 +6,549	+23%	+$177K	﹤0.01%	2208
2026 Q1	$512K	Sell	28,454 -588,152	-95%	-$11.8M	﹤0.01%	2449
2025 Q4	$14.4M	Buy	616,606 +259,991	+73%	+$5.64M	﹤0.01%	1149
2025 Q3	$7.12M	Sell	356,615 -4,826	-1%	-$86.7K	﹤0.01%	1308
2025 Q2	$4.95M	Sell	361,441 -7,213	-2%	-$69.2K	﹤0.01%	1267
2025 Q1	$4.08M	Sell	368,654 -25,330	-6%	-$270K	﹤0.01%	1308
2024 Q4	$4.2M	Buy	393,984 +381,145	+2,969%	+$4.56M	﹤0.01%	1332
2024 Q3	$164K	Buy	12,839 +1,891	+17%	+$28.1K	﹤0.01%	2714
2024 Q2	$184K	Sell	10,948 -256,195	-96%	-$3.64M	﹤0.01%	2611
2024 Q1	$4.01M	Buy	+267,143	New	+$4.37M	﹤0.01%	1282

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

T. Rowe Price Associates's URGN Position: Q2 2026 in Review

T. Rowe Price Associates increased its UroGen Pharma (URGN) stake by 23% in Q2 2026, buying an estimated $177K and bringing the position to 35,003 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

T. Rowe Price Associates first reported a position in URGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $14.4M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

T. Rowe Price Associates held 35,003 shares of UroGen Pharma worth $1.29M as of Q2 2026.
T. Rowe Price Associates bought 6,549 UroGen Pharma shares in Q2 2026, an estimated $177K.
UroGen Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2208 holding.
T. Rowe Price Associates first reported a position in UroGen Pharma in Q1 2024 and has held it in 10 quarters since.
T. Rowe Price Associates's UroGen Pharma position peaked at $14.4M in Q4 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.